BR112018011045A2 - inibidores de oligonucleotídeo anti-sentido (aso) de transportador de monocarboxilato 4 (mct4) para uso como terapêutica no tratamento de câncer - Google Patents

inibidores de oligonucleotídeo anti-sentido (aso) de transportador de monocarboxilato 4 (mct4) para uso como terapêutica no tratamento de câncer

Info

Publication number
BR112018011045A2
BR112018011045A2 BR112018011045A BR112018011045A BR112018011045A2 BR 112018011045 A2 BR112018011045 A2 BR 112018011045A2 BR 112018011045 A BR112018011045 A BR 112018011045A BR 112018011045 A BR112018011045 A BR 112018011045A BR 112018011045 A2 BR112018011045 A2 BR 112018011045A2
Authority
BR
Brazil
Prior art keywords
cancer
mct4
aso
antisense
therapy
Prior art date
Application number
BR112018011045A
Other languages
English (en)
Inventor
C Collins Colin
Xue Hui
E Gleave Martin
Wilhelm Gout Peter
Yiu Chuen Choi Stephen
Wang Yuzhuo
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of BR112018011045A2 publication Critical patent/BR112018011045A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

são aqui fornecidas composições, método e usos para modular a atividade de mct4 ou para o tratamento de câncer. as composições compreendem oligonucleotídeos anti-sentido (aso) para administração a uma célula de câncer, em que a célula de câncer pode ser caracterizada por expressão elevada de mct4. o câncer pode ser selecionado de um ou mais de: câncer de próstata; carcinoma de células renais; câncer de mama; câncer cervical; câncer de fígado; câncer de bexiga; e câncer de pulmão de pequenas células pr. o câncer de próstata pode ser câncer de próstata resistente à castração (crpc).
BR112018011045A 2015-11-30 2016-11-30 inibidores de oligonucleotídeo anti-sentido (aso) de transportador de monocarboxilato 4 (mct4) para uso como terapêutica no tratamento de câncer BR112018011045A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260837P 2015-11-30 2015-11-30
PCT/CA2016/000296 WO2017091885A1 (en) 2015-11-30 2016-11-30 Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112018011045A2 true BR112018011045A2 (pt) 2018-11-21

Family

ID=58795956

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011045A BR112018011045A2 (pt) 2015-11-30 2016-11-30 inibidores de oligonucleotídeo anti-sentido (aso) de transportador de monocarboxilato 4 (mct4) para uso como terapêutica no tratamento de câncer

Country Status (10)

Country Link
US (2) US10889814B2 (pt)
EP (1) EP3384028B1 (pt)
JP (1) JP7039470B2 (pt)
CN (1) CN108603194A (pt)
AU (1) AU2016363683B2 (pt)
BR (1) BR112018011045A2 (pt)
CA (1) CA3006827A1 (pt)
ES (1) ES2893294T3 (pt)
MX (1) MX2018006527A (pt)
WO (1) WO2017091885A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3006827A1 (en) 2015-11-30 2017-06-08 The University Of British Columbia Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer
MX2019001389A (es) 2019-01-31 2020-02-20 Atso Corp Affairs S A De C V Oligonucleotidos antisentido de las glutation s transferasa para el tratamiento del cancer.
WO2022250466A1 (ko) * 2021-05-27 2022-12-01 사회복지법인 삼성생명공익재단 전립선암의 엔잘루타미드 저항성 억제용 약학 조성물 및 엔잘루타미드 저항성을 가지는 전립선암 치료용 약학 조성물
CN113717971A (zh) * 2021-08-10 2021-11-30 南通大学 PGK1靶向siRNA干扰库及其应用
CN114246829B (zh) * 2021-12-31 2023-03-24 北京大学 一种反义核酸药物的包载方法、由该方法制备得到的药物制剂及其在肝癌治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004993A2 (de) 1997-07-21 1999-02-04 Christoph Schuster Kraftfahrzeug mit einem verschliessbaren fahrerraum
ATE385237T1 (de) * 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
US20030059781A1 (en) * 2000-03-21 2003-03-27 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
US6637473B2 (en) 2000-10-30 2003-10-28 Robodesign International, Inc. Automated storage and retrieval device and method
DK1545561T3 (da) 2002-10-02 2010-08-02 Univ British Columbia Oligonucleotider til behandling af prostata og andre cancersygdomme
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
GB2407837B (en) * 2003-11-04 2007-07-11 Corus Uk Ltd Traffic control barriers
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
FI3198035T3 (fi) * 2014-09-26 2023-01-31 Menetelmiä lääkevasteen ennustamiseksi
CA3006827A1 (en) 2015-11-30 2017-06-08 The University Of British Columbia Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer

Also Published As

Publication number Publication date
AU2016363683A1 (en) 2018-07-12
US20210395733A1 (en) 2021-12-23
EP3384028A1 (en) 2018-10-10
AU2016363683B2 (en) 2023-04-27
WO2017091885A1 (en) 2017-06-08
JP2019500334A (ja) 2019-01-10
CN108603194A (zh) 2018-09-28
US20190010492A1 (en) 2019-01-10
US11466273B2 (en) 2022-10-11
ES2893294T3 (es) 2022-02-08
EP3384028A4 (en) 2019-05-01
MX2018006527A (es) 2018-11-29
WO2017091885A8 (en) 2018-06-07
US10889814B2 (en) 2021-01-12
EP3384028B1 (en) 2021-06-30
CA3006827A1 (en) 2017-06-08
JP7039470B2 (ja) 2022-03-22

Similar Documents

Publication Publication Date Title
BR112018011045A2 (pt) inibidores de oligonucleotídeo anti-sentido (aso) de transportador de monocarboxilato 4 (mct4) para uso como terapêutica no tratamento de câncer
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
SG10201902664RA (en) Combination therapy for treating cancer
BR112017013597A2 (pt) molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença.
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
WO2016025635A3 (en) Combination therapy for treating cancer
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BR112019004322A2 (pt) moduladores de receptor glicocorticoide para tratar câncer pancreático
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
EA201991622A1 (ru) Комплексная терапия для лечения рака
BR112018006039A2 (pt) terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
WO2016043874A3 (en) Combination therapy for treating cancer
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112016028641A2 (pt) ?método para tratar câncer?
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
EA201891473A1 (ru) Комбинированная терапия
BR112018002530A2 (pt) combinações e usos e tratamentos destas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]